Abivax Presents 22 Studies on Obefazimod at the ECCO 2026 Congress
Biotechnology company Abivax has announced the acceptance of 22 scientific abstracts concerning its drug candidate obefazimod for chronic inflammatory bowel diseases, to be presented at the 21st annual congress of the European Crohn's and Colitis Organisation in February 2026 in Stockholm.
Diverse Presentations Highlighting Clinical Data
According to the press release, the accepted works include one oral presentation, five digital oral presentations, and sixteen posters. These studies particularly leverage data from the phase 3 ABTECT induction trials, which were double-blind and placebo-controlled, in moderately to severely active ulcerative colitis. Subgroup analyses, the group notes, demonstrate obefazimod's clinical activity across different patient sub-populations. The data also covers the evolution of pro-inflammatory cytokines such as IL-17A and IL-6, as well as early symptom improvement and the treatment's tolerance profile.
Oral Presentation on Preclinical Data Scheduled
The oral presentation set for Saturday, February 21, 2026, will unveil new preclinical data concerning a complication of Crohn's disease, the company indicates. The study assessed the antifibrotic effects of obefazimod in an in vitro fibrosis model using human small intestine fibroblasts, as well as in an in vivo murine model of TNBS-induced colitis. According to Abivax, intestinal fibrosis, characterized by excessive scar tissue formation, is a serious complication that can lead to stenosis often requiring surgical intervention. The release emphasizes that no effective antifibrotic treatment is currently available for patients with chronic inflammatory bowel diseases.
Abivax: A Clinical-Stage Biotechnology Company
Abivax is a clinical-stage biotechnology company based in France and the United States, the document specifies. Its lead drug candidate, obefazimod, is currently undergoing phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The ECCO congress, to be held from February 18 to 21, 2026 in Stockholm, will provide an opportunity to showcase the research progress on this compound to the European scientific community specializing in Crohn's disease and colitis.
